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Key messages
 ► A substantial proportion of COPD patients received a 
second course of antibiotics within fourteen days of 
the index prescription.
 ► Amoxicillin was prescribed most commonly as the 
index drug and was associated with fewer repeat 
antibiotic prescriptions.
 ► Shorter index courses were not associated with 
more repeat prescriptions.
AbstrAct
Introduction Antibiotics are routinely given to people with 
chronic obstructive pulmonary disease (COPD) presenting 
with lower respiratory tract infection (LRTI) symptoms 
in primary care. Population prescribing habits and their 
consequences have not been well-described.
Methods We conducted a retrospective analysis of 
antibiotic prescriptions for non-pneumonic exacerbations 
of COPD from 2010 to 2015 using the UK primary care 
Optimum Patient Care Research Database. As a proxy of 
initial treatment failure, second antibiotic prescriptions for 
LRTI or all indications within 14 days were the primary and 
secondary outcomes, respectively. We derived a model for 
repeat courses using univariable and multivariable logistic 
regression analysis.
results A total of 8.4% of the 9042 incident events 
received further antibiotics for LRTI, 15.5% further 
courses for any indication. Amoxicillin and doxycycline 
were the most common index and second-line drugs, 
respectively (58.7% and 28.7%), mostly given for 7 
days. Index drugs other than amoxicillin, cardiovascular 
disease, pneumococcal vaccination and more primary care 
consultations were statistically significantly associated 
with repeat prescriptions for LRTI (p<0.05). The ORs and 
95% CIs were: OR 1.28, 95% CI 1.10 to 1.49; OR 1.37, 
95% CI 1.13 to 1.66; OR 1.33, 95% CI 1.14 to 1.55 and 
OR 1.05, 95% CI 1.02 to 1.07, respectively. Index duration, 
inhaled steroid use and exacerbation frequency were not 
statistically significant. The derived model had an area 
under the curve of 0.61, 95% CI 0.59 to 0.63.
Discussion The prescription of multiple antibiotic courses 
for COPD exacerbations was relatively common—one 
in twelve patients receiving antibiotics for LRTI had a 
further course within 2 weeks. The findings support the 
current preference for amoxicillin as index drug within the 
limitations of this observational study. Further clinical trials 
to determine best practice in this common clinical situation 
appear required.
IntroDuctIon
Lower respiratory tract infections (LRTIs) 
are globally the most common infectious 
cause of morbidity.1 Despite this prevalence, 
observed duration of antibiotic treatment 
for LRTI varies greatly, and there is disagree-
ment between guidelines on the optimal 
duration.2 Effective first-line treatment for 
non-pneumonic LRTI in chronic obstructive 
pulmonary disease (COPD) patients (‘infec-
tive exacerbations’) is an area of particular 
uncertainty.
COPD is a common cause of disability, and 
estimated to become the third leading cause 
of death worldwide in 2030.3–5 Exacerbations 
form a large part of the disease burden and 
can lead to a cough with discoloured phlegm 
irrespective of causation. Over £250 million is 
spent on treating COPD exacerbations annu-
ally in the UK, and recurrent exacerbations 
are associated with increased morbidity and 
mortality.6
Up to half of all COPD exacerbations 
are thought to be caused by bacteria, the 
remainder by viruses or environmental irri-
tants.7–10 The most common pathogens are 
Haemophilus influenzae, Moraxella catarrhalis 
and Streptococcus pneumoniae.6 Initial studies 
suggested that the administration of anti-
biotics was associated with a lower risk of 
symptom persistence.11 However, a Cochrane 
review concluded that a statistically significant 
improvement in treatment failure rate was 
only seen in severe exacerbations, with more 
adverse events in the antibiotic group.7 Hence, 
the European Respiratory Society/American 
Thoracic Society and international guide-
lines advise, based on moderate evidence, 
the prescription of antibiotics for ambulatory 
patients ‘if clinically indicated’.12 13 However, 
our understanding of the success of real-life 
prescribing practices is limited.
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The risk of treatment failure without antibiotics needs 
to be balanced with antimicrobial resistance, contributed 
to by inappropriate and non-evidence based prescribing, 
and adverse drug effects, including Clostridium difficile 
infection.14–16 Primary care is an optimal environment 
to improve antibiotic use since 74% of all UK antibi-
otics are prescribed here and around three-quarters of 
patients presenting in primary care with an acute COPD 
exacerbation receive antibiotics.17–19 Moreover, a Euro-
pean-wide COPD audit of hospitalised patients demon-
strated that antibiotics were more likely to be continued 
during admissions and after discharge if they had already 
been received in primary care.20
Guidelines on antibiotics for COPD exacerbations are 
not specific and based only on moderate evidence. The 
National Institute of Health and Care Excellence guide-
lines for the study period suggest using an aminopeni-
cillin, macrolide or tetracycline but give no indication on 
duration.21 The Global Initiative for Chronic Obstructive 
Lung Disease advises 5–7 days duration but no antibiotic 
class.13 A recent meta-analysis presented dirithromycin, 
ofloxacin and ciprofloxacin as having the best cure and 
side-effect profiles, yet these are not used routinely in 
clinical practice.22
In this study, we characterised patterns of antibiotic 
prescribing for COPD exacerbations via a retrospective 
observational analysis of primary care data from 2010 to 
2015. We explored the factors associated with the risk of 
further antibiotic prescription, which may form the basis 
for future comparative interventional studies, such as 
clinical trials comparing different antibiotic durations, 
or first-line drugs in specific patient groups.
MethoDs
We carried out a cross-sectional database study drawing 
on retrospective, electronic medical records from the 
Optimum Patient Care Research Database (OPCRD). 
Individuals were included if they had an active diagnosis 
of COPD during the study period, demonstrated by their 
primary care coding.
We included COPD patients who received at least one 
antibiotic prescription with an LRTI read code from 01 
April 2010 to 01 April 2015. LRTI codes included those for 
chest infection and bronchitis. We analysed only the first 
event for each individual to exclude repeated measure-
ments from the same patient. Primary outcome was a 
new antibiotic prescription with an LRTI code within 14 
days of the index prescription. Secondary outcome was 
further antibiotic prescription within 14 days for any 
indication. We excluded cases with a coded diagnosis of 
pneumonia, other chronic respiratory diseases, such as 
asthma, people younger than 16 years and those whose 
index antibiotic course was either not specified or was 
longer than 28 days.
Data source
The OPCRD comprised data extracted through the 
Optimum Patient Care Clinical Service Evaluation 
(http:// optimumpatientcare. org/ opcrd/). The OPCRD 
is a quality-controlled, primary care research database 
focussing on respiratory disease. It contained anony-
mous, routinely recorded electronic medical records 
data from over 525 UK general practices.
statistical analysis
Data were analysed using SPSS V.22. We examined 
multiple factors to assess the risk of repeat antibiotic 
prescription for LRTI or any indication, including demo-
graphics, smoking status, comorbidities, COPD disease 
control, including medication and interactions with 
secondary care, and index antibiotic duration and class.
Individual factors were first assessed using univariable 
analysis. Univariably, mean differences in continuous 
variables were analysed via t-tests, while ORs for binary 
variables were analysed via logistic regression. Multivari-
able models were built using logistic regression with back-
wards selection. Summary statistics,  χ2  and Student t tests 
were presented as appropriate for each variable, based 
on type and distribution of data. Statistically significant 
results were defined as p<0.10 for univariable analysis 
(to show trends) and p<0.05 for multivariable analysis. 
Collinear associations between clinically plausible-related 
predictors were assessed using Pearson’s correlation coef-
ficients. Factors were included in the multivariable model 
based on clinical plausibility. Adjusted ORs and CIs were 
presented where appropriate. Visual inspection of the 
functional form of each continuous variable suggested 
that no transformation was required. Multivariable 
models were derived via backwards parsimonious logistic 
regression, including linear regression for mean differ-
ences, and the resulting models were tested for goodness 
of fit.
results
Demographics
There were 22 003 unique prescriptions for LRTI in 
adult COPD patients between 01 January 2010 and 31 
December 2015 in the OPCRD. The mean age was 71 
years and 48.2% were women. A total of 45.6% were 
ex-smokers and 42.4% were current smokers, 4.9% 
were never-smokers (smoking status was missing in 
7.1%). Most patients were from the Midlands and East 
England (58.9%). The most common LRTI codes were 
for ‘chest infection’ (44.3%), ‘acute exacerbation of 
chronic obstructive airways disease’ (28.1%) and ‘lower 
respiratory tract infection’ (17.3%). Table 1 describes the 
baseline demographics and all variables included in the 
univariable analysis.
A total of 9042 (41%) patients had a documented 
index antibiotic duration for LRTI and were included in 
the analysis (figure 1). Individuals receiving antibiotics 
for an uncertain duration (eg, only number of tablets 
documented) were excluded, as were a small number 
of individuals with treatment durations over 28 days. 
Most index courses were prescribed for 7 days (75.7%), 
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Table 1 Baseline demographics of all individuals included 
in the study
Variable
All patients (n=22 003)
Number (%) unless 
otherwise indicated
Female sex 10 605 (48.2)
Age (years), mean±SD 70.83±10.9
BMI (kg/m2), mean±SD 27.2±6.1
  Smoking status
  Non-smoker 1081 (4.9)
  Current smoker 9326 (42.4)
  Ex-smoker 10 033 (45.6)
  Missing 1563 (7.1)
Primary and secondary care 
consultations
  Number of respiratory consultations in 
primary care*
  1 4371 (19.9)
  2 7823 (35.6)
  3 4269 (19.4)
  ≥4 3445 (25.1)
Number of all consultations in primary 
care*, mean±SD
12.9±9
Number who had at least one inpatient 
admission for respiratory code*
326 (1.4)
  Exacerbations*
  0 10 203 (46.4)
  1 6831 (31.0)
  2 2729 (12.4)
  ≥3 2240 (10.2)
  Lung function
  FEV1 (L), mean±SD 1.43±0.61
  FEV1/FVC ratio, mean±SD 0.59±0.3
  COPD treatment
  Number of SABA prescriptions*, 
mean±SD
4.78±5.3
  Number using ICS 12 925 (58.7)
  Number of LAMA prescriptions*, 
mean±SD
3.02±4.5
  Number of LABA inhalers*, mean±SD 0.41±2.0
  No treatment 2718 (12.4)
  Vaccinations
  Influenza vaccination ever 13 894 (63.1)
  Pneumococcal vaccination ever 6860 (31.2)
Blood eosinophil count closest to index 
antibiotic prescription, mean±SD
0.31±0.5
  Recorded comorbidity
  Diabetes 3286 (14.9)
  Anxiety/depression 1811 (8.2)
  Cardiovascular disease 2407 (10.9)
  Concurrent medications
  Paracetamol prescription* 10 554 (48.0)
Continued
Variable
All patients (n=22 003)
Number (%) unless 
otherwise indicated
  Location
  London 86 (0.4)
  Midlands and East 12 965 (58.9)
  North 4577 (20.8)
  South 32 349 (14.8)
  Missing 1126 (5.1)
*In year prior to index prescription.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, 
forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting 
beta-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-
acting beta-agonist.
Table 1 Continued
Figure 1 Flow chart of inclusion and exclusion for study 
analysis of antibiotic prescriptions in COPD patients in the 
OPCRD database, April 2010–April 2015. COPD, chronic 
obstructive pulmonary disease; LRTI, lower respiratory 
tract infection; OPCRD, Optimum Patient Care Research 
Database.
10.5% received shorter and 13.8% received longer index 
courses. Amoxicillin, doxycycline and clarithromycin 
were used most commonly (58.7%, 14.0% and 11.7% 
respectively, see figure 2A). The median index duration 
was 8 days for doxycycline and 7 days for all other agents.
repeat prescriptions for lrtI
A total of 764 (8.4%) patients received a second antibiotic 
course for LRTI within 14 days of the index prescription. 
The most commonly prescribed antibiotics were doxy-
cycline, erythromycin/clarithromycin and amoxicillin 
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Figure 2 Treemap chart of antibiotic duration and drug of 
(A) index prescriptions and (B) repeat prescriptions for LRTI. 
Absolute numbers presented. Missing data due to missing 
duration (127 cases). a, amoxicillin; b, erythromycin/
clarithromycin; c, doxycycline; d, co-amoxiclav; e, other; 
LRTI, lower respiratory tract infection.
(28.7%, 27.3% and 25.8%, respectively, see figure 2B). 
Most second-line prescriptions were for 7, 8 or 5 days 
(73.5%, 9.8% and 8.6%, respectively). The median for 
repeat antibiotic course duration was 7 days. A total of 
127 cases had no documented second-course duration.
In the univariable analysis, those who received further 
antibiotics were statistically significantly older, had more 
comorbidities and had more severe disease as measured 
by higher consultation frequency, more COPD exacer-
bations in the past year and more COPD medications 
(table 2). Index drug and location were significantly asso-
ciated with repeat prescription. Smoking status, FEV1 
(forced expiratory volume in 1 s), index duration and 
ICS (inhaled corticosteroids) treatment were not signifi-
cantly associated with repeat prescriptions (supplemen-
tary files).
Collinearity was assessed for all statistically significant 
(p<0.10) factors in univariable analysis. The Pearson’s 
correlation coefficient was in excess of 0.8 between the 
clinically related pairs of number of oral steroid courses 
and exacerbation number, number of respiratory and 
all secondary care outpatient appointments, number of 
ICS inhalers and prescriptions, pure LAMA (long-acting 
muscarinic antagonist) prescription and inhalers, and 
pure LABA (long-acting beta-agonist) prescription and 
inhalers. We, hence, used exacerbation number, respi-
ratory outpatient appointments, ICS, LAMA and LABA 
inhalers in the multivariable analysis.
The derived parsimonious multivariable model 
included index antibiotic, number of primary care 
consultations for respiratory and all complaints, number 
of LABA inhalers in previous year, presence of cardio-
vascular disease and previous pneumococcal vaccination 
(p<0.05, table 2). Those not receiving amoxicillin as 
index antibiotic, who had previously received the pneu-
mococcal vaccine, with cardiovascular disease, more 
LABA inhalers or more respiratory or all primary care 
consultations, were at increased risk of repeat antibiotics 
for LRTI.
The model fitted the dichotomous outcome with a 
Cox-Snell R2 of 0.013 (area under the curve (AUC) 0.61, 
95% CI 0.59 to 0.63). Introducing interaction terms 
between clinically logical factors did not improve the fit 
of the model (supplementary files).
repeat prescriptions for all indications
A total of 1430 patients received a second antibiotic 
course for any indication (15.5%). Twenty-four of these 
received two courses within 14 days of index prescription 
and were, hence, excluded from further analysis. Doxy-
cycline, amoxicillin and erythromycin/clarithromycin 
were used most (28.9%, 27.0% and 26.6%, respectively, 
supplementary figure 1) for durations of 7, 8 and 5 days 
(71.4%, 9.2% and 8.1%, respectively). The antibiotics 
included in the ‘all indications’ analysis were amoxicillin, 
doxycycline, erythromycin, clarithromycin, co-amoxiclav, 
cephalexin, cefaclor and ciprofloxacin, all of which are 
used to treat LRTI. The median duration was 7 days. 
A total of 304 cases did not have a documented repeat 
duration.
Smoking status, number of emergency department and 
outpatient appointments, FEV1 as well as ICS treatment 
were statistically significant (p<0.05) in the univariable 
analysis (supplementary files).
The presence of cardiovascular disease, index drug other 
than amoxicillin, number of all primary care consultations 
and exacerbations as well as number of ICS and LAMA 
inhalers were significantly associated with repeat antibiotic 
prescription in the multivariable parsimonious regression 
analysis (p<0.05). Model-checking showed a Cox-Snell R2 
of 0.012 (AUC 0.58, 95% CI 0.56 to 0.60).
DIscussIon
summary
In this analysis of COPD exacerbations in UK primary care, 
we studied over 9000 antibiotic prescriptions for LRTI 
over 5 years. The majority of patients received 7-day index 
courses and amoxicillin was the most commonly given 
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Table 2 Results of statistically and clinically significant univariable and multivariable analysis for repeat antibiotic prescription 
for LRTI code within 14 days of index duration. Univariable analysis according to type of data
Variable
Univariable analysis results
Multiple logistic regression 
model results
OR
95 % CI
Mean difference
95% CI P value
OR
95 % CI P value
Age −0.66
−1.4 to 0.1
0.10
Location <0.01
  Midlands and East Index
  London 0.59
0.21 to 1.62
0.30
  North 0.74
0.60 to 0.91
<0.01
  South 0.77
0.64 to 0.93
0.01
Gastro-oesophageal reflux disease diagnosis 1.53
1.03 to 2.27
0.03
Cardiovascular disease diagnosis 1.63
1.34 to 1.95
<0.01 1.37
1.13 to 1.66
<0.01
Paracetamol prescription* 1.18
1.02 to 1.37
0.03
Pneumococcal vaccination 1.38
1.19 to 1.60
<0.01 1.33
1.14 to 1.55
<0.01
Number of primary care respiratory 
consultations*
−1.05
−1.29 to 0.82
<0.01 1.05
1.02 to 1.07
<0.01
Number of all primary care consultations* −3.16
−3.89 to −2.43
<0.01 1.01
1.01 to 1.02
<0.01
Number of OCS* −0.10
−0.20 to 0.00
0.05
Number of exacerbations* −0.10
−0.20 to −0.01
0.06
FEV1 value (L) 0.02
−0.03 to 0.07
0.38
Count of ICS inhalers* −0.41
−0.87 to 0.05
0.08
Count of LAMA prescriptions* −0.33
−0.67 to 0.01
0.06
Count of LABA inhalers* −0.20
−0.36 to −0.04
0.02 1.03
1.00 to 1.05
0.08
Count of LTRA prescriptions* 0.04
−0.16 to 0.00
0.06
Not amoxicillin as index antibiotic 1.37
1.18 to 1.58
<0.01 1.28
1.10 to 1.49
<0.01
Blank entries relate to variables not included in the multivariable model.
*In year prior to index prescription.
FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic 
antagonist; LRTI, lower respiratory tract infection; LTRA, Leukotriene receptor antagonist;OCS, oral corticosteroid.
drug. A large proportion of antibiotic prescriptions had no 
explicitly recorded duration. A substantial proportion of 
patients (15.5%) received further antibiotics within 14 days 
of the index antibiotic prescription. Over half of the repeat 
prescriptions within 14 days were coded for another LRTI 
(52.1%). Amoxicillin as index drug was associated with 
fewer repeat prescriptions. Older age and some markers 
of COPD severity were associated with increased risk of 
apparent initial treatment failure.
strengths and limitations
One of the strengths of the study is the genuine, unse-
lected primary care population as demonstrated, 
for example, by 97.2% not having had a respiratory 
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Figure 3 Second-line antibiotics used for LRTI by initial 
antibiotic: (A) amoxicillin and (B) not amoxicillin. Missing 
data due to missing drug name (23 cases). LRTI, lower 
respiratory tract infection.
outpatient appointment and 46.4% not having had an 
exacerbation in the prior year. This contrasts with most 
interventional studies which have highly selected patient 
populations—for example, it has been estimated that 
only up to 7% of people treated for COPD meet inclu-
sion criteria for randomised trials.23 Real-life data, such as 
this, have an important role in helping to inform real-life 
decision-making.
We analysed electronic health records. In the era 
of advancing electronic records, there is a drive to use 
more routinely collected data particularly in primary 
care research, for example, by the National Institute 
for Health Research or highlighted in the Salford Lung 
Study, to reduce burden on patients, bias and approxi-
mate real-world practice.24 25 However, the reliance on 
primary care data is also this study’s major limitation—
chiefly, the 59% of patients for whom no duration was 
clearly documented for their index duration of antibi-
otics. This reflects the true documentation practice in 
primary care, where coding can be challenging.26 We 
are unable to distinguish appropriate from inappro-
priate antibiotic prescribing using this large primary 
care database, in keeping with large variation in antibi-
otic prescribing in primary care found in other studies 
that could not entirely be explained by patient charac-
teristics.27 It is also likely that other factors, such as pres-
ence of purulent sputum or prior microbiology results, 
influenced decisions for repeat antibiotic prescribing. A 
cross-sectional primary care study in Europe, Asia and 
South America showed that purulent sputum and use of 
C reactive protein were the strongest predictors of initial 
antibiotic prescribing in COPD exacerbations.18
We examined more antibiotic courses over 5 years 
than an earlier primary care COPD exacerbation analysis 
from 2005 to 2010.27 This study of 12 609 exacerbations 
also showed a high prevalence of antibiotic prescribing 
within 7 days of presentation (66% cases). We also 
reported repeat antibiotic prescribing for any indica-
tion to ensure no LRTI prescriptions were missed as not 
all repeat prescriptions for LRTI will have been coded 
appropriately.
We were limited by the potential for missing data on 
secondary care contacts (eg, emergency department 
attendances and hospital admissions) and use of other 
healthcare services (eg, out of hours and walk-in centres). 
The imperfect recording of such data is anticipated to 
lead to an underestimate of the true number of repeat 
prescriptions issued as lack of improvement increases 
the probability of accessing providers other than the 
patient’s usual general practitioner. We acknowledge that 
some treatment failures would result in hospitalisation, 
and these could be incorrectly coded as if the treatment 
was successful (ie, no repeat course of antibiotics from 
primary care). However, community-treated exacerba-
tions of COPD are far more common than hospitalisa-
tions, and most people admitted have not completed 
antibiotics in the community, so any effect on the anal-
yses would be modest.20 There was no explicit coding for 
repeat or continuous antibiotics in this data set. However, 
such prescriptions would have been excluded (as we did 
not include antibiotic courses that had a duration that 
was either not specified or was longer than 28 days) 
unless they were rotating antibiotics which are used very 
rarely, for example, 1 patient in over 92 000 cases studied 
in a large retrospective primary care analysis.28 The use of 
long-term antibiotics in COPD patients remains rare (eg, 
0.61% in the above study) and no long-term studies exist 
in these patients.28–30 Our study is also limited by primary 
care coding of COPD rather than the use of source data, 
such as lung function.
setting in current literature and future directions
Durations of 7 days remained most prominent across 
different situations, but index duration was not signif-
icantly associated with further prescriptions. When 
encountering treatment failure, the decision was to 
change drug rather than duration (figure 3)—studies 
are needed to investigate whether this is the correct 
approach. There is limited evidence and guidance 
on ideal index duration for antibiotics.13 21 A recent 
meta-analysis found that adverse effects in COPD patients 
were more prevalent when the same index antibiotic was 
given for more than 7 days compared with less than 7 days 
with no difference in clinical outcomes.31 A large retro-
spective analysis of UK primary care data showed that 
respiratory infections were responsible for the majority of 
antibiotics prescribed for longer than guidelines suggest, 
with 89% of COPD exacerbations receiving more than 
the recommended 5 days of treatment.32 In primary care, 
asthma patients 7-day courses were also associated with 
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fewer repeat prescriptions.33 Our study also supports the 
consideration of shorter index durations, but interven-
tional studies are needed to confirm this.
Prior pneumococcal vaccination was associated with 
repeat antibiotic prescription. Vaccination did not appear 
to be a proxy of comorbidity, age or frequency of primary 
care attendance given its appearance in the final multi-
variable model, that interaction analysis did not improve 
the model and there was no collinearity. In previous 
studies, pneumococcal vaccination has been shown to 
reduce vaccine-specific disease but not overall rates of 
LRTI.34 It is, therefore, possible that these vaccinated 
patients may have had a true bacterial infection that was 
not susceptible to the common index drugs. Owing to the 
observational, retrospective nature of the analysed data 
sets, the causality of effects is difficult to ascertain. This is 
particularly true given a further limitation of our study: 
sputum culture results were not sufficiently commonly or 
systematically recorded to be included in the analyses.
ICS have previously shown to be associated with 
increased risk of pneumonia, particularly older and more 
severely airway constrained patients.35–37 These factors 
were associated with apparent treatment failure in our 
univariable analyses, but not in the final models.
Amoxicillin, doxycycline and erythromycin/clarithro-
mycin were the most commonly used antibiotics. The 
prevalence of amoxicillin decreased from 58.7% to 25.8% 
in the repeat prescriptions but remained an important 
contributor. This may reflect practitioners attempting to 
address relevant pathogens, such as M. catarrhalis and H. 
influenzae, in the repeat courses that are usually resistant 
to penicillins.38 However, in contrast to this, not using 
amoxicillin as index antibiotic was significantly associated 
with the risk of repeat prescriptions for LRTI and all indi-
cations. This warrants further investigation on the patho-
gens of these exacerbations, particularly to differentiate 
true failure of antibiotic action from unacceptable side 
effects from the index treatment. Respiratory viruses 
were identified in almost 40% of patients with COPD 
exacerbations and only 40%–50% of exacerbations were 
thought to be caused by bacteria.9 10 Non-bacterial exac-
erbations would improve irrespective of antibiotic treat-
ment and inappropriately treated exacerbations may 
present as treatment failure.
conclusIon
Prescription of further antibiotics for LRTI occurred 
commonly in UK primary care COPD patients from 2010 
to 2015. Our data supported usage of amoxicillin as index 
drug. Shorter index durations were not associated with 
more repeat prescriptions. Prior consultations, pneumo-
coccal vaccine, presence of cardiovascular disease and 
index drug were associated with the decision to prescribe 
a second course. Interventional studies on the optimal 
drug and duration for common subsets of people with 
COPD in primary care are needed to properly inform 
guidelines for this common clinical problem.
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